Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alice Tsang Shaw, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Alice Shaw and Anthony Iafrate.
Connection Strength

5.359
  1. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20; 371(21):1963-71.
    View in: PubMed
    Score: 0.609
  2. Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. N Engl J Med. 2011 Jul 14; 365(2):158-67.
    View in: PubMed
    Score: 0.487
  3. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10; 27(26):4247-53.
    View in: PubMed
    Score: 0.427
  4. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019 Jul; 30(7):1121-1126.
    View in: PubMed
    Score: 0.218
  5. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019 07 01; 30(7):1121-1126.
    View in: PubMed
    Score: 0.212
  6. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 06; 8(6):714-729.
    View in: PubMed
    Score: 0.194
  7. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 2017.
    View in: PubMed
    Score: 0.186
  8. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 05; 12(5):872-877.
    View in: PubMed
    Score: 0.178
  9. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
    View in: PubMed
    Score: 0.172
  10. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2016 08; 11(8):1242-1245.
    View in: PubMed
    Score: 0.172
  11. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016 Jan 07; 374(1):54-61.
    View in: PubMed
    Score: 0.166
  12. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1670-4.
    View in: PubMed
    Score: 0.165
  13. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014 Nov 15; 20(22):5686-96.
    View in: PubMed
    Score: 0.152
  14. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013 Jun 20; 368(25):2395-401.
    View in: PubMed
    Score: 0.139
  15. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013 Aug 01; 19(15):4273-81.
    View in: PubMed
    Score: 0.139
  16. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012 Oct; 13(10):1011-9.
    View in: PubMed
    Score: 0.132
  17. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012 Mar 10; 30(8):863-70.
    View in: PubMed
    Score: 0.126
  18. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011 Oct; 12(11):1004-12.
    View in: PubMed
    Score: 0.123
  19. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. J Clin Oncol. 2011 May 20; 29(15_suppl):7507.
    View in: PubMed
    Score: 0.121
  20. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 03; 108(18):7535-40.
    View in: PubMed
    Score: 0.120
  21. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6.
    View in: PubMed
    Score: 0.117
  22. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
    View in: PubMed
    Score: 0.116
  23. Clinicopathologic features of EML4-ALK mutant lung cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):11021.
    View in: PubMed
    Score: 0.105
  24. Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. J Thorac Oncol. 2020 09; 15(9):1497-1506.
    View in: PubMed
    Score: 0.056
  25. Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. J Thorac Oncol. 2019 05; 14(5):835-843.
    View in: PubMed
    Score: 0.051
  26. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
    View in: PubMed
    Score: 0.050
  27. Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clin Cancer Res. 2019 01 01; 25(1):158-165.
    View in: PubMed
    Score: 0.050
  28. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. Ann Oncol. 2018 09 01; 29(9):1964-1971.
    View in: PubMed
    Score: 0.050
  29. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.050
  30. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.050
  31. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol. 2018 04 20; 36(12):1199-1206.
    View in: PubMed
    Score: 0.048
  32. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.048
  33. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis Oncol. 2017; 1(1):5.
    View in: PubMed
    Score: 0.045
  34. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov. 2015 Jul; 5(7):713-22.
    View in: PubMed
    Score: 0.040
  35. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014 Dec 19; 346(6216):1480-6.
    View in: PubMed
    Score: 0.038
  36. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 08; 4(120):120ra17.
    View in: PubMed
    Score: 0.032
  37. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624.
    View in: PubMed
    Score: 0.031
  38. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2011 May 20; 29(15_suppl):2501.
    View in: PubMed
    Score: 0.030
  39. SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol. 2011 May 20; 29(15_suppl):7518.
    View in: PubMed
    Score: 0.030
  40. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23; 3(75):75ra26.
    View in: PubMed
    Score: 0.030
  41. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2010 Jun 20; 28(18_suppl):3.
    View in: PubMed
    Score: 0.028
  42. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 Aug 15; 15(16):5216-23.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.